Michael Egan

Cooley represented Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, in its $234.6 million initial public offering and concurrent $17 million private placement.

Cooley advised Avid Bioservices (Nasdaq: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, on its definitive merger agreement to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion.

Cooley advised Cents, the top all-in-one business management platform powering garment care small- and medium-sized businesses (SMBs), on its $40 million Series B financing, as well as its acquisition of Laundroworks, a hardware-based payments system powering how consumers pay for laundry at laundromats and shared laundry rooms within multifamily buildings, hotels, universities and more.

Cooley advised Blue Owl Capital (NYSE: OWL), a top asset manager that is redefining alternatives, and HealthCare Royalty (HCRx), a top royalty acquisition company focused on commercial or near-commercial biopharmaceutical products, on a $250 million term loan facility with TG Therapeutics (NASDAQ: TGTX), a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

Cooley advised Mott Corporation – a microfiltration business specializing in the design, customization, and manufacturing of sintered porous metal components and engineered solutions used in fluidic applications – on its definitive agreement to sell to IDEX Corporation for cash consideration of $1 billion, subject to customary adjustments.